SNS-102 / Sensei Biotherap - LARVOL DELTA

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) - "Recent updates include: Sensei has completed lead optimization for its programs SNS-102 (targeting VSIG4) and SNS-103 (targeting CD-39) and is currently characterizing potential lead antibodies for each program. Sensei remains on track to select product candidates for both SNS-102 and SNS-103 in 2023. Sensei’s early discovery bispecific antibody program has generated an initial set of conditionally active bispecific antibodies that are currently being characterized. Upon successful candidate selection, Sensei expects to advance one product candidate to IND-enabling studies."

Pipeline update • Oncology • Solid Tumor

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire) - "Upcoming Milestones: Sensei will present preclinical data on its SNS-103 program at the American Association for Cancer Research (AACR) Annual Meeting in a poster session on April 18, 2023. Sensei remains on track to select product candidates for both SNS-102 and SNS-103 in 2023. Upon successful candidate selection, Sensei expects to advance at least one product candidate to IND-enabling studies....R&D expenses were $30.4 million for the year ended December 31, 2022, compared to $21.7 million for the year ended December 31, 2021. The increase in R&D expenses was primarily attributable to increased manufacturing and early development activities for the Company’s lead program SNS-101, partially offset by a decrease in clinical trial expenses."

Commercial • Preclinical • Oncology • Solid Tumor

Functional characterization of the inhibitory activity and identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4 (SITC 2022) - "VSIG4 (V-Set and Immunoglobulin domain containing 4) is a negative checkpoint regulator (NCR) and its expression has been well established on both tissue resident macrophages and TAM populations...A group of T-cell receptors was found to be involved in novel interactions with VSIG4, and their potential roles in VSIG4-mediated regulation are currently being validated. Collectively, our work will lead to an enhanced mechanistic understanding of how VSIG4 suppresses T-cell activation and provide a strategy and tools for discovery of therapeutic relevant anti-VSIG4 antibodies."

IO biomarker • Oncology

Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) - "SNS-101: The Company intends to present new data from a multi-dose pharmacokinetic (PK) and toxicology model in non-human primates in the first half of 2023. Sensei remains on track to select a product candidate for SNS-102 in 2023; SNS-103: The Company began screening the first set of parental antibodies in September 2022 and remains on track to select a product candidate in 2023."

Clinical • Preclinical • Oncology • Solid Tumor

Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire) - "Sensei Biotherapeutics...announced it will present two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA from November 8 - 12, 2022."

Preclinical • Oncology

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) - "SNS-101 has demonstrated great manufacturing productivity to date and Sensei anticipates reviewing pharmacokinetic and toxicology data from its single dose non-human primate studies in mid-2022. Sensei has initiated GMP manufacturing for SNS-101 and remains on track to submit an IND in the first half of 2023; Sensei intends to select a product candidate and initiate IND-enabling studies in 2023 for SNS-102, a monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), a B7-family related protein that is frequently overexpressed on tumor-associated macrophages."

IND • New trial • Preclinical • Oncology • Solid Tumor

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights (GlobeNewswire) - "In August, Sensei announced it had selected SNS-101, a potent pH-dependent product candidate that selectively blocks the interaction of VISTA with its receptor, PSGL-1, in the low pH tumor microenvironment; VSIG4 (V-Set and Immunoglobulin Domain Containing 4)...Sensei plans to select a product candidate from this program in 2023; SNS-401-NG...Sensei intends to initiate IND-enabling studies for this product candidate in the second half of 2022."

Clinical • Pipeline update • Oncology • Solid Tumor